Drugs / Descartes-25
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05113342 | Nov 2021 → May 2023 | plasma cell myeloma | Cartesian Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Descartes-25 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05113342 ↗ |
| Modality | Cell therapy | “allogeneic Mesenchymal Stem Cell product.” NCT05113342 ↗ |